Variant Bio

People-Driven Therapeutics

[Variant Bio @VariantBio]

Right on the heels of our press release announcing a deal with Novo Nordisk, we're thrilled to see this NY Times coverage of the partnership and Variant Bio's ethics-first approach to drug discovery: https://t.co/ehNLqmvPch

[Metabolon, Inc. @Metabolon]

Join our webinar with Dr. Olivia Gray (@VariantBio) tomorrow!

Learn how multiomics revealed mechanisms affecting creatinine-based eGFR estimates in African ancestry populations.

📅 27 May
🕒 11 am EDT | 5 pm CEST

🔗https://t.co/mQVsUg0tOS

[Metabolon, Inc. @Metabolon]

Can genetics bias kidney disease biomarkers?

In our next webinar, Dr. Olivia Gray (@VariantBio) will show how multiomics revealed mechanisms affecting creatinine-based eGFR estimates in African ancestry populations.

📅 27 May
🕑 11 am EDT | 5 pm CEST

🔗 https://t.co/mQVsUg0tOS

[Variant Bio @VariantBio]

Variant Bio recently launched a new study focused on diabetes in Bangladesh in partnership with Novo Nordisk and icddr,b: https://t.co/UdmqGsPdW1

[Variant Bio @VariantBio]

In honor of International Nurses Day -- celebrated on the anniversary of Florence Nightingale's birth -- the team @VariantBio owes a huge THANK YOU to nurses around the world (including in Tahiti, pictured here) who make our research studies possible. Cheers to nurses everywhere!

[Variant Bio @VariantBio]

Dr. Moira Gunn from @biotechnation interviewed @AndrewFarnum and Dr. Sarah LeBaron von Baeyer from @VariantBio for NPR this week on how AI, ethics, and diverse data can help us develop better drugs and diagnostics: https://t.co/nEzBug4Wqo

[Andrew Farnum @AndrewFarnum]

Alpha in biotech comes from looking where no one else is. At @VariantBio, we’ve built a proprietary engine to uncover human genetic evidence that the rest of the industry is missing. I had a great deep dive into the ethics and science of our approach on @biotechnation today.

[Andrew Farnum @AndrewFarnum]

Thank you for hosting a great conversation on our work @VariantBio, Dr. Moira Gunn! @biotechnation https://t.co/XLcAInWKKc

[Variant Bio @VariantBio]

“In the era of precision medicine, [a]dding more data from the global north may offer only incremental insight, whereas African data has the potential for genuinely novel discovery. It is a meaningful step toward inclusion and equity”: https://t.co/Pp1glZE0hI

[Variant Bio @VariantBio]

In honor of National Doctors' Day today, we would like to thank all the doctors we have worked with in partner communities around the world, as well as the doctors who are committed to helping patients with the new medicines we are developing @VariantBio.

[Variant Bio @VariantBio]

Coverage of Variant Bio's collaboration with Prof. Lyn Griffiths and the QUT Centre for Genomics and Personalised Health on the genetic and multi-omic landscape of metabolic conditions in Pasifika communities in Australia: https://t.co/E3UQOpnTgf

[Variant Bio @VariantBio]

Variant Bio recently launched a study with Novo Nordisk, this time in partnership with the University of Otago and Pukapuka Community Group: https://t.co/r1O7goSEeL

[Variant Bio @VariantBio]

We published an open-access article on how to apply flexible benefit-sharing models to genomic research projects in South Africa and beyond: https://t.co/CYksKF3OfS

[Variant Bio @VariantBio]

An anthropologist and a geneticist from Variant Bio teamed up with partners in New Caledonia to return study results one island at a time: https://t.co/5Vph1maqkY

[Variant Bio @VariantBio]

Coverage in @geekwire's Tech Moves today (https://t.co/fH0RXx40Ap):

[Variant Bio @VariantBio]

We are thrilled to welcome Dr. Craig Basson to our team at Variant Bio! Read more here: https://t.co/R4HzrWqTNX

[Variant Bio @VariantBio]

Coinciding with our most recent pharma collaboration, we officially launched our Inference agentic AI platform and an accompanying website: https://t.co/tPlo1RN8CY

[Health Technology Insights @HealthTech_IA]

@VariantBio and Boehringer Ingelheim are teaming up to advance research focused on kidney diseases

Read the full story here 👇
https://t.co/d1OGWzJf3w

[Josh Wolfe @wolfejosh]

1/ Big news today from Lux family co Variant Bio 🧬📈@VariantBio

Announced its new Inference platform is now available to research partners + has collaborations with several pharmaceutical companies in deals totaling more than $200 million including Boehringer + Novo Nordisk...

[Josh Wolfe @wolfejosh]

2/ Variant Bio @VariantBio has just revealed

https://t.co/Xr6Nsyw1UC

the world's first agentic AI genomic discovery platform

[Longevity Technology @LongevityTech]

Harnessing genomics and AI agents in drug discovery, platform underpins new kidney disease collaboration with Boehringer Ingelheim.

https://t.co/q1uYhqC2uD

#longevity #biotech #drugdiscovery #AI #pharma